Sarepta Therapeutics has acquired 1 company.
Sarepta Therapeutics’ largest acquisition to date was in 2019, when it acquired Myonexus Therapeutics for $165M. Sarepta Therapeutics has acquired in 1 US state. The Company’s most targeted sectors include life science (100%).
215 First Street, Suite 415,
Cambridge, Massachusetts
02142
United States,
(617) 274-4000
www.sarepta.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2019-02-27 |
Myonexus Therapeutics · Life Science
New Albany, Ohio · www.myonexustx.com Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first ever treatments for limb girdle muscular dystrophies (LGMDs) based on research at Nationwide Children’s Hospital, a provider in neuromuscular gene therapy discovery and translational research. Myonexus Therapeutics was founded in 2017 and is based in New Albany, Ohio. Advisors: Fenwick & West , Thompson Hine , William Blair |
165 | Add-on Acquisition | - |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
